Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi

Acta Tropica

Volumn 75, Issue 2, 2000, Pages 219-228

  Santa Rita, Ricardo M ^a   Santos Barbosa, Helene ^a   Meirelles, Maria De Nazareth S L ^a   De Castro, Solange L ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Alkyl lysophospholipids; Chemotherapy; Edelfosine; ET 18 OCH3; Trypanosoma cruzi

Indexed keywords

ALKYLLYSOPHOSPHOLIPID; ANTIPARASITIC AGENT; EDELFOSINE; ILMOFOSINE; MILTEFOSINE;

AMASTIGOTE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; EPIMASTIGOTE; HEART MUSCLE CELL; MOUSE; NONHUMAN; TRYPANOSOMA CRUZI; TRYPOMASTIGOTE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART; LIFE CYCLE STAGES; LYSOPHOSPHOLIPIDS; MACROPHAGES; MICE; MICROSCOPY, ELECTRON; PHOSPHOLIPID ETHERS; PHOSPHORYLCHOLINE; TEMPERATURE; TIME FACTORS; TRYPANOSOMA CRUZI;

TRYPANOSOMA; TRYPANOSOMA CRUZI; VIOLA (ANGIOSPERM);

EID: 0034712428     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-706X(00)00052-8     Document Type: Article

References (52)

1. Berdel W.E. Ether lipids and derivatives as investigational anticancer drugs. A brief review. Onkologie. 13:1990;245-250.
2. Berdel W.E. Membrane-interative lipids as experimental anticancer drugs. Br. J. Cancer. 64:1991;208-211.
3. Berdel W.E., Bauseert W.R., Weltzien H.U., Modolell M.L., Widmann K.H., Munder P.G. The influence of alkyl-lysophospholipids and lysophospholipids-activated macrophages on the development of metastasis of 3-Lewis lug carcinona. Eur. J. Cancer. 16:1980;1199-1203.
4. Berdel W.E., Fromm M., Fink U., Pahlke W., Bicker U., Reichert A., Rastetter J. Cytotoxicity of thioether-lysophospholipids in leukemia and tumors of human origin. Cancer Res. 43:1983;5538-5542.
5. 2+ concentration in a normal and a breast cancer cell line. Anticancer Res. 14:1994;549-556.
6. Bourass J., Loiseau P.M., Letourneux Y. Antileishmanial activity of rac-1-dodecyl-2-octanamido-2-deoxy-glycerophosphocholine a new dialkylglycerophosphocholine, in vitro. Ann. Trop. Med. Parasitol. 90:1996;559-561.
7. Brachwitz H., Vollgraf C. Analogs of alkyl lysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignat cells. Pharmacol. Ther. 66:1995;39-82.
8. Camargo E.C. Growth and differentiation in Trypanosoma cruzi. Origin of metacyclic trypanosomes in liquid media. Rev. Inst. Med. Trop. São Paulo. 6:1964;93-100.
9. Contreras V.T., Araújo-Jorge T.C., Bonaldo M.C., Thomaz N., Barbosa H.S., Meirelles M.N.L., Goldenberg S. Biological aspects of the Dm28c clone of Trypanosoma cruzi after metacyclogenesis in chemically defined media. Mem. Inst. Oswaldo Cruz. 83:1988;123-133.
10. Croft S.L., Snowdon D., Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. Chemother. 38:1996;1041-1047.
11. Croft S.L., Urbina J.A., Brun R. Chemotherapy of human leishmaniasis and trypanosomiasis. Hide G., Mottram J.C., Coombs G.H., Holmes P.H. Trypanosomiasis and Leishmaniasis. 1997;245-257 Cab. International, NY USA.
12. Daniel L.W., Etkin L.A., Morrison B.T., Parker J., Morris-Natschke S., Surles J.R., Piantadosi C. Ether lipids inhibit the effects of phorbol diester tumor promoters. Lipids. 22:1987;851-855.
13. de Castro S.L. The challenge of Chagas' disease chemotherapy: an update of drugs assayed against Trypanosoma cruzi. Acta Trop. 53:1993;83-98.
14. de Castro S.L., Meirelles M.N.L., Oliveira M.M. Trypanosoma cruzi: adrenergic modulation of cAMP role in proliferation and differentiation of amastigotes in vitro. Exp. Parasitol. 64:1987;368-375.
15. de Castro S.L., Pinto M.C.F.R., Pinto A.V. Screening of natural and synthetic drugs against Trypanosoma cruzi. 1. Establishing a structure/activity relationship. Microbios. 78:1994;83-90.
16. De Conti R., Santa Rita R.M., de Souza E.M., Melo P.S., Haun M., de Castro S.L., Duran N. In vitro trypanocidal activities of a novel series of N,N-dimethyl-2-propen-1-amine derivative. Microbios. 85:1996;83-87.
17. De Souza W. Cell biology of Trypanosoma cruzi. Int. Rev. Cytol. 86:1984;197-283.
18. Diomede L., Piovani B., Modest E.J., Salmona M. The effect of culture medium composition on ether lipid cytotoxic activity. Lipids. 28:1993;189-192.
19. Gonzales-Perdomo M., Romero P., Goldenberg S. cAMP and adenylate cyclase activators stimulate Trypanosoma cruzi differentiation. Exp. Parasitol. 66:1988;205-212.
20. Heesbeen E.C., Rijksen G., van Heugten H.G., Verdonck L.F. Influence of serum levels on leukemic cell destruction by the ether lipid edelfosine. Leuk. Res. 19:1995;417-425.
21. 2+-dependent protein phosphorylation system in various types of leukemic cells from human patients and in human leukemic cell lines HL60 and K562, and its inhibition by alkyl-lysophospholipid. Cancer Res. 43:1983;2955-2961.
22. Kelley E.E., Modest E.J., Burns C.P. Unidirectional membrane uptake of the ether lipid antineoplastic agent edelfosine by L1210 cells. Biochem. Pharmacol. 45:1993;2435-2439.
23. Konstantinov S.M., Kaminsky R., Brun R., Berger M.R., Zillmann U. Efficacy of anticancer alkylphosphocholines in Trypanosoma brucei subspecies. Acta Trop. 64:1997;145-154.
24. Kuhlencord A., Maniera T., Eibl H., Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob. Agents Chemother. 36:1992;1630-1634.
25. Lazenby C.M., Thompson M.G., Hickman J.A. Elevation of leukemic cell intracellular calcium by the ether lipid SRI 62-834. Cancer Res. 50:1990;3327-3330.
26. Lohmeyer M., Workman P. The role of intracellular free calcium mobilization in the mechanism of action of antitumour ether lipids SRI 62-834 and ET18-Ome. Biochem. Pharmacol. 45:1993;77-86.
27. Lopes J.N., Cruz F.S., Do Campo R., Vasconcellos M.E., Sampaio M.C.R., Pinto A.V., Gilbert B. In vitro and in vivo evaluation of the toxicity of 1,4-naphthoquinone and 1,2-naphthoquinone derivatives against Trypanosoma cruzi. Ann. Trop. Med. Parasitol. 72:1978;523-531.
28. Meirelles M.N.L., Araújo-Jorge T.C., Miranda C.F., Barbosa H.S. Interaction of Trypanosoma cruzi with heart muscle cells: ultrastructural and cytochemical analysis of endocytic vacuole formation and effect upon myogenesis in vitro. Eur. J. Cell Biol. 41:1986;198-205.
29. Modolell M., Andreesen R., Pahlke W., Brugger U., Munder P.G. Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids. Cancer Res. 39:1979;4681-4686.
30. 3. Biochem. Biophys. Res. Commun. 192:1993;603-609.
31. Moncayo, A. (1993) Chagas' disease. Tropical Disease Report - Progress 1991-1992. 11th Progress Report of the UNDP/World Bank/WHP Special Program for Training in Tropical Diseases. World Health Organization, Geneva.
32. Moreno S.N., Silva J., Vercesi A.E., Docampo R. Cytosolic-free calcium elevation in Trypanosoma cruzi is required for cell invasion. J. Exp. Med. 180:1994;1535-1540.
33. Munder, P.G., Fischer, H., Weltzien, H.U., Oettgen, H.F., Modolell, M., 1976. Lysolecithin analogs: a new class of immunopotentiators with antitumor activity. Proceedings of AACR, pp. 174.
34. Noseda A., Berens M.E., White J.G., Modest E.J. In vitro antiproliferative activity of combinations of ether lipid analogues and DNA-interactive agents against human tumor cells. Cancer Res. 48:1988;1788-1791.
35. Noseda A., White J.G., Godwin P.L., Jerome W.G., Modest E.J. Membrane damage in leukemic cells induced by ether and ester lipids: an electron microscopic study. Exp. Mol. Pathol. 50:1989;69-83.
36. Petersen E.S., Kelley E.E., Modest E.J., Burns C.P. Membrane lipid modification and sensitivity of leukemic cells to the thioether lipid analogue BM 41.440. Cancer Res. 52:1992;6263-6269.
37. Planting A.S., Stoter G., Verweij J. Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur. J. Cancer. 29A:1993;8-9.
38. Powis G., Seewald M.J., Gratas C., Melder D., Riebow J., Modest E.J. Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. Cancer Res. 52:1992;2835-2840.
39. Rangel-Aldao R., Allende O., Triana F., Piras R., Henriquez D., Piras M. Possible role of cAMP in the differentiation of Trypanosoma cruzi. Mol. Biochem. Parasitol. 22:1987;39-43.
40. Rovai L.E., Aoki A., Gerez de Burgos N.M., Blanco A. Effect of gossypol on trypomastigotes and amastigotes of Trypanosoma cruzi. J. Protozool. 37:1990;280-286.
41. 2+ signaling by antitumor ether lipid analogues. Cancer Res. 50:1990;4458-4463.
42. Sundar S., Rosenkaimer F., Makharia M.K., Goyal A.K., Mandal A.K., Voss A., Hilgard P., Murray H.W. Trial of oral miltefosine for visceral leishmaniasis. Lancet. 352:1998;1821-1823.
43. Tidwell T., Guzman G., Vogler W.R. The effect of alkyl-lysophospholipids on leukemic cell lines. I. Differential action on two human leukemic cell lines, HL60 and K562. Blood. 57:1981;794-797.
44. Tsushima S., Yoshioka Y., Tanida S., Nomura H., Nojima S., Hozumi M. Synthesis and antimicrobial activities of alkyl lysophospholipids. Chem. Pharm. Bull. 30:1982;3260-3270.
45. Unger C., Damenz W., Fleer E.A., Kim D.J., Breiser A., Hilgard P., Engel J., Nagel G., Eibl H. Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. Acta Oncol. 28:1989;213-217.
46. Vagnetti D., Mancini A., Santarella B., Binaglia L. Effect of alkyl-lysophospholipid analogs on the morphology of a murine lymphoma cell line. J Submicrosc. Cytol. Pathol. 22:1990;415-424.
47. Van Blitterswijk W.J., Hilkmann H., Storme G.A. Accumulation of an alkyl lysophospholipid in tumor cell membranes affects membrane fluidity and tumor cell invasion. Lipids. 22:1987;820-823.
48. Vogler W.R., Whigham E., Bennett W.D., Olson A.C. Effect of alkyl-lysophospholipids on phosphatidylcholine biosynthesis in leukemic cell lines. Exp. Hematol. 13:1985;629-633.
49. Vogler W.R., Berdel W.E., Geller R.B., Brochstein J.A., Beveridge R.A., Dalton W.S., Miller K.B., Lazarus H.M. A phase II trial of autologous bone marrow transplantation (ABMT) in acute leukemia with edelfosine purged bone marrow. Adv. Exp. Med. Biol. 416:1996;389-396.
50. Vogler W.R., Shoji M., Hayzer D.J., Xie Y.P., Renshaw M. The effect of edelfosine on CTP:cholinephosphate cytidylyltransferase activity in leukemic cell lines. Leuk. Res. 20:1996;947-951.
51. Wieder T., Haase A., Geilen C.C., Orfanos C.E. The effect of two synthetic phospholipids on cell proliferation and phosphatidylcholine biosynthesis in Madin-Darby canine kidney cells. Lipids. 30:1995;389-393.
52. Winkelmann M., Ebeling K., Strohmeyer G., Hottenrott G., Mechl Z., Berges W., Scholten T., Westerhausen M., Schlimok G., Sterz R. Treatment results of the thioether lipid ilmofosine in patients with malignant tumours. J. Cancer Res. Clin. Oncol. 118:1992;405-407.